Affinivax snags $226m Series C

Affinivax Inc, a clinical-stage biopharmaceutical company, has raised $226 million in Series C financing.

Affinivax Inc, a clinical-stage biopharmaceutical company, has raised $226 million in Series C financing. Rock Springs Capital and Foresite Capital led the round.

Source: Press Release